- Home
- UHT vs BCYC Comparison
UHT vs BCYC Comparison
Compare UHT & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHT
- BCYC
- Stock Information
- Founded
- UHT 1986
- BCYC 2009
- Country
- UHT United States
- BCYC United Kingdom
- Employees
- UHT 5
- BCYC N/A
- Industry
- UHT Real Estate Investment Trusts
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- UHT Real Estate
- BCYC Health Care
- Exchange
- UHT Nasdaq
- BCYC Nasdaq
- Market Cap
- UHT 515.7M
- BCYC 492.1M
- IPO Year
- UHT N/A
- BCYC 2019
- Fundamental
- Price
- UHT $37.17
- BCYC $7.96
- Analyst Decision
- UHT
- BCYC Buy
- Analyst Count
- UHT 0
- BCYC 11
- Target Price
- UHT N/A
- BCYC $22.91
- AVG Volume (30 Days)
- UHT 79.6K
- BCYC 303.4K
- Earning Date
- UHT 10-23-2025
- BCYC 10-30-2025
- Dividend Yield
- UHT 7.95%
- BCYC N/A
- EPS Growth
- UHT N/A
- BCYC N/A
- EPS
- UHT 1.30
- BCYC N/A
- Revenue
- UHT $99,952,000.00
- BCYC $19,281,000.00
- Revenue This Year
- UHT N/A
- BCYC N/A
- Revenue Next Year
- UHT $0.81
- BCYC N/A
- P/E Ratio
- UHT $28.63
- BCYC N/A
- Revenue Growth
- UHT 0.31
- BCYC N/A
- 52 Week Low
- UHT $34.56
- BCYC $6.10
- 52 Week High
- UHT $43.52
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- UHT 32.82
- BCYC 58.20
- Support Level
- UHT $38.60
- BCYC $7.40
- Resistance Level
- UHT $39.36
- BCYC $8.69
- Average True Range (ATR)
- UHT 0.96
- BCYC 0.38
- MACD
- UHT -0.47
- BCYC 0.11
- Stochastic Oscillator
- UHT 7.96
- BCYC 62.23
About UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.